Replies to post #402942 on Anavex Life Sciences Corp (AVXL)

[bb8675309]

Bravo, georgejjl. Good post. Imo - That patent is probably worth $10 to $15 billion in early application. Nice!

[jimmy_mcyoloswag]

FYI, all the essays in the patent appear to have been performed in a specialised contract lab from eurofins:

https://www.eurofins.fr/contacts/eurofins-cerep-france/

[georgejjl]

A pharmaceutical preparation comprising -A2-73 substantially free of + A2-73. This invention further includes a method treating Alzheimer's disease in a subject in need of such treatment by the method of administering a therapeutically effective amount of -A2-73 substantially free of + A2-73.

This invention yet further includes a method of classifying cells as to sigma receptor type by the method of exposing said cells to a detectable amount of - A2-73 substantially free of + A2-73 and determining the level of sigma receptor binding.

https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/20230044710

Good luck and GOD bless,

[nidan7500]

georgejji---thx for this

NEW PATENT APPLICATION FOR ANAVEX LIFE SCIENCES

ENANTIOMERS OF A2-73, ANALOGUES,
CO7D 231/22
(2006.01)
AND SIGMA AGONIST ACTIVITY

Applicant: Anavex Life Sciences Corp., New
Inventor: Gervais Neliat, Le Bois L'Eveque (FR)
Appl. No.: 17/959,920

A2-730 is a selective noncompetitive agonist for o1 receptors and a significantly stronger agonist than A2-73



https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/20230044710

Good luck and GOD bless,

Excellent stuff. This would be exactly the kind of evidence expected as the science continues to grow and evolve over time. Results matter but we might expect Dr.M. and team are leaders in a CNS evolution which has a massive undefined scope.

Unclear if the existing WW methods for defining, linked CNS diseases is going to be adequate for defining/identifying everything, including rare diseases. Very interesting human systems stuff yet to be learned, IMO.

[Jager997]

I find this patent absolutely fascinating (polarizing at optical frequencies). However, it looks like a variant of A2-73 and what does that mean for future approval and trials?